期刊文献+

羟基喜树碱联合奥沙利铂对人肺癌细胞作用的体外研究 被引量:5

In vitro interactions between hydroxycamptothecine and oxaliplatin on human lung carcinoma cell line
下载PDF
导出
摘要 目的:体外观察羟基喜树碱(hydroxycamptothecine,HCPT)联合奥沙利铂(oxaliplatin,L-OHP)对人肺癌A549细胞增殖的协同抑制作用,并初步探讨其机制。方法:采用SRB法测定HCPT和L-OHP对A549细胞增殖的抑制作用,根据中效原理判断两药合用时的效应。采用显微镜、流式细胞仪观察两药对A549细胞的诱导凋亡作用。结果:HCPT和L-OHP均能明显抑制A549细胞增殖和诱导细胞凋亡,两药合用具有协同作用。结论:HCPT联合L-OHP能协同抑制A549细胞增殖,其机制可能是通过协同诱导凋亡。 Objective:To study the combined effect of hydroxycamptothecine(HCPT) and oxaliplatin( L- OHP) on human lung adenocarcinoma A549 cells in vitro, and investigate the possible mechanism. Methods: Cell growth inhibition was assesed by Sulforhodamine - B technique. Median - effect analysis was used to determine interactions between HCPT and L - OHP. Apoptotic cells was detected by fluorescence microscope and flow eytometry. Results: HCPT and L - OHP given alone or in combination could inhibit the growth of A549 cells effectively. Combination treatment had synergistic cytotoxicity on A549 cells. Both HCPT and L - OHP could induce the apoptosis of A549 cells, and apoptotic rate was obviously elevated by combination treatment. Conclusion: HCPT and L - OHP in combination showed synergistic cytotoxicity on A549 cells. Combination treatment induced more apoptosis of A549 cells, it maybe involved in the mechanism of the synergistic cytotoxicity.
出处 《现代肿瘤医学》 CAS 2009年第2期206-208,共3页 Journal of Modern Oncology
关键词 羟基喜树碱 奥沙利铂 肺癌细胞 协同作用 凋亡 hydroxycamptothecine oxaliplatin lung carcinoma synergistic effect apoptosis
  • 相关文献

参考文献11

  • 1Chou TC, Motzer R J, Tong Y, et al. Computerized quantitation of synergism and antagonism of taxol, topotecan, and cisplatin against human teratocarcinoma cell growth: a rational approach to clinical protocol design [ J ]. J Natl Cancer Inst, 1994,86 (20) : 1517 - 1524.
  • 2Chou TC, Talalay P. Quantitative analysis of dose - effect relationships: the combined effects of muhiple drugs or enzyme inhibitors [J]. Adv Enzyme Regul, 1984,22:27 -55.
  • 3顾建春,郑磊贞,陈强.羟基喜树碱在进展期非小细胞肺癌中的应用[J].中国肿瘤临床与康复,2006,13(5):475-477. 被引量:1
  • 4黄慧强,姜文奇,胡晓桦,林旭滨,刘魁凤,李宇红,林忠,申维玺,陈强,何友兼,管忠震.羟基喜树碱冻干粉针(拓僖)单药治疗晚期恶性肿瘤临床研究的初步报告[J].癌症,2003,22(12):1334-1338. 被引量:32
  • 55 Fukuda M, Nishio K, Kanzawa F, et al. Synergism between cisplatin and topoisomerase I inhibitors, NB - 506 and SN - 38, in human small cell lung cancer ceils [ J ]. Cancer Res, 1996,56 (4) :789 -793.
  • 6Goldwasser F, Bozec L, Zeghari - Squalli N, et al. Cellular pharmacology of the combination of oxaliplatin with topotecan in the IGROV - 1 human ovarian cancer cell line[J]. Anticancer Drugs, 1999,10(2) :195 -201.
  • 7Zeghari - Squalli N, Raymond E, Cvitkovic E, et al. Cellular pharmacology of the combination of the DNA topoisomerase Ⅰ inhibitor SN -38 and the diaminocyclohexane platinum derivative oxaliplatin[J]. Clin Cancer Res, 1999,5(5) :1189 - 1196.
  • 8Guichard S, Amould S, Hennebelle I, et al. Combination of oxaliplatin and irinotecan on human colon cancer cell lines: activity in vitro and in vivo [J]. Anticancer Drugs, 2001,12 (9) :741 - 751.
  • 9Kanzawa F, Koizumi F, Koh Y, et al. In vitro synergistic interactions between the cisplatin analogue nedaplatin and the DNA topoisomerase Ⅰ inhibitor irinotecan and the mechanism of this interaction[J]. Clin Cancer Res, 2001,7( 1 ) :202 -209.
  • 10Goldwasser F, Shimizu T, Jackman J, et al. Correlations between S and G2 arrest and the cytotoxicity of camptothecin in human colon carcinoma cells [ J ]. Cancer Res, 1996,56 ( 19 ) : 4430 - 4437.

二级参考文献24

  • 1徐腾云,胡冰,庄建生.羟基喜树碱、顺铂及长春新碱联合治疗晚期非小细胞肺癌34例[J].肿瘤研究与临床,2001,13(3):176-177. 被引量:1
  • 2王怀瑾,赵卫红,孙玲,高文斌,戚晓军,张雪梅,尹良伟,董淑英.HP与NP方案治疗晚期非小细胞肺癌的随机对照研究[J].中华肿瘤杂志,2004,26(7):420-420. 被引量:4
  • 3Zunino F,Dallavalleb S,Laccabuea D,et al.Current status and perspectives in the development of camptothecins[J].Curr Pharm Des,2002,8(27):2505-2520.
  • 4Slichenmyer WJ,Rowinsky EK,Donehower RC,et al.The current status of camptothecin analogues as antitumor agents[J].J Nat Canc Inst,1993,85(4):271-291.
  • 5Aisner J,Musanti R,Beers S,et al.Sequencing topotecan and etoposide plus cisplatin to overcome topoisomerase Ⅰ and Ⅱ resistance:a pharmacodynamically based phase Ⅰ trial[J].Clin Cancer Res,2003,9(7):2504-2509.
  • 6Guichard S,Arnould S,Hennebelle I,et al.Combination of oxaliplatin and irinotecan on human colon cancer cell lines:activity in vitro and in vivo[J].Anticancer Drugs,2001,12(9):741-751.
  • 7Wu HG,Choy H.Irinotecan in combination with radiation therapy for small-cell and non-small-cell lung cancer[J].Oncology(Huntingt),2002,16(9):13-18.
  • 8Kim JS,Amorino GP,Pyo H,et al.Radiation enhancement by the combined use of topoisomerase Ⅰ inhibitors,RFS-2000 or CPT-11,and topoisomerase Ⅱ inhibitor etoposide in human lung cancer cells[J].Radiother Oncol,2002,62(1):61-67.
  • 9李华峰.羟基喜树碱协同放疗治疗中晚期非小细胞肺癌[J].浙江肿瘤,1999,5(4):244-244.
  • 10刘键.羟基喜树碱类药物作用机制及在合并治疗中机理的研究[J].中国肿瘤临床,1998,25(5):389-392. 被引量:162

共引文献31

同被引文献33

引证文献5

二级引证文献15

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部